Australia's most trusted
source of pharma news
Friday, 23 January 2026
Posted 22 January 2026 PM
Telix has reported 46 per cent year-on-year revenue growth for the fourth quarter of 2025, as it begins its push to launch Illuccix into China.
The second-largest pharma by market cap listed on the ASX reported revenue for Q4 2025 of $306 million (US$208 million), up 46 per cent compared to Q4 2024, and one per cent compared to the third quarter of 2025. It capped off the full-year earnings at $1.2 billion (US$804 million) for 2025.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.